Metastatic Breast Cancer – Pipeline Review, H1 2013

Published: June 2013
No. of Pages: 438
   

Summary

Global Markets Direct’s, ''Metastatic Breast Cancer - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer. Metastatic Breast Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Breast Cancer.
  • A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Breast Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Metastatic Breast Cancer – Pipeline Review, H1 2013

Table Of Contents

Table Of Contents 2
List of Tables 6
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Metastatic Breast Cancer Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Metastatic Breast Cancer 12
Metastatic Breast Cancer Therapeutics under Development by Companies 14
Metastatic Breast Cancer Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 22
Comparative Analysis 22
Mid Clinical Stage Products 23
Comparative Analysis 23
Early Clinical Stage Products 24
Comparative Analysis 24
Discovery and Pre-Clinical Stage Products 25
Comparative Analysis 25
Metastatic Breast Cancer Therapeutics – Products under Development by Companies 26
Metastatic Breast Cancer Therapeutics – Products under Investigation by Universities/Institutes 33
Companies Involved in Metastatic Breast Cancer Therapeutics Development 34
Bristol-Myers Squibb Company 34
Johnson & Johnson 35
F. Hoffmann-La Roche Ltd. 36
Kyowa Hakko Kirin Co., Ltd. 37
Biogen Idec Inc. 38
Amgen Inc. 39
Adherex Technologies Inc. 40
AstraZeneca PLC 41
Eli Lilly and Company 42
GlaxoSmithKline plc 43
Seattle Genetics, Inc. 44
Genentech, Inc. 45
Nektar Therapeutics 46
Bavarian Nordic A/S 47
MedImmune LLC 48
Merck & Co., Inc. 49
Celltrion, Inc. 50
ZIOPHARM Oncology, Inc. 51
Millennium Pharmaceuticals, Inc. 52
Novartis AG 53
Aphios Corporation 54
Biocon Limited 55
Eisai Co., Ltd. 56
GTx, Inc. 57
Laboratoires Pierre Fabre SA 58
Nippon Kayaku Co., Ltd. 59
Pfizer Inc. 60
Taiho Pharmaceutical Co., Ltd. 61
Cell Therapeutics, Inc. 62
Enzon Pharmaceuticals, Inc. 63
Celgene Corporation 64
Bayer AG 65
Celldex Therapeutics, Inc. 66
Oncolytics Biotech Inc. 67
Peregrine Pharmaceuticals, Inc. 68
Bionovo, Inc. 69
Array BioPharma Inc. 70
Starpharma Holdings Limited 71
Jiangsu Hengrui Medicine Co., Ltd. 72
Synta Pharmaceuticals Corp. 73
Natco Pharma Limited 74
Transgene Biotek Ltd 75
Wilex AG 76
INSYS Therapeutics, Inc. 77
Supratek Pharma Inc. 78
Meabco A/S 79
BioNumerik Pharmaceuticals, Inc. 80
Alligator Bioscience AB 81
MacroGenics, Inc. 82
Fresenius Biotech GmbH 83
PTC Therapeutics, Inc. 84
Advenchen Laboratories, LLC 85
Immutep S.A. 86
Syndax Pharmaceuticals, Inc. 87
NewLink Genetics Corporation 88
PharmaMar, S.A. 89
WntResearch AB 90
TRACON Pharmaceuticals, Inc. 91
Regulus Therapeutics Inc. 92
Merus B.V. 93
Aragon Pharmaceuticals, Inc. 94
EirGen Pharma Ltd. 95
Immunovative Therapies, Ltd. 96
Metastatic Breast Cancer – Therapeutics Assessment 97
Assessment by Monotherapy Products 97
Assessment by Combination Products 98
Assessment by Route of Administration 99
Assessment by Molecule Type 101
Drug Profiles 104
eribulin mesylate - Drug Profile 104
BMS-754807 - Drug Profile 108
brivanib alaninate - Drug Profile 110
trebananib - Drug Profile 113
entinostat - Drug Profile 116
lonaprisan - Drug Profile 120
icrucumab - Drug Profile 121
cetuximab - Drug Profile 122
cixutumumab - Drug Profile 128
ado-trastuzumab emtansine - Drug Profile 131
ado-trastuzumab emtansine - Drug Profile 134
RG-7422 - Drug Profile 137
enobosarm - Drug Profile 139
pertuzumab - Drug Profile 141
pertuzumab - Drug Profile 143
brostallicin - Drug Profile 145
neratinib - Drug Profile 147
neratinib - Drug Profile 151
pictrelisib - Drug Profile 155
onartuzumab - Drug Profile 157
firtecan pegol - Drug Profile 159
abiraterone acetate - Drug Profile 161
dusigitumab - Drug Profile 163
etirinotecan pegol - Drug Profile 165
trastuzumab biosimilar - Drug Profile 167
panobinostat - Drug Profile 168
paclitaxel - Drug Profile 173
BIIB-021 - Drug Profile 175
dimesna - Drug Profile 177
pixantrone - Drug Profile 179
APH-0912 - Drug Profile 182
frondoside A - Drug Profile 183
ganitumab - Drug Profile 184
paclitaxel albumin-bound - Drug Profile 187
fulvestrant - Drug Profile 189
Anti-Angiogenesis Agent 2C3 - Drug Profile 191
dasatinib - Drug Profile 192
ramucirumab - Drug Profile 194
ramucirumab - Drug Profile 198
glembatumumab vedotin - Drug Profile 202
ganetespib - Drug Profile 203
ARRY-380 - Drug Profile 207
BZL-101 - Drug Profile 209
varlitinib - Drug Profile 211
pelareorep - Drug Profile 213
palifosfamide tromethamine - Drug Profile 217
SP-1012C - Drug Profile 219
orantinib - Drug Profile 220
BP-C1 - Drug Profile 222
YN-968D1 - Drug Profile 223
bavituximab - Drug Profile 226
tivozanib - Drug Profile 231
ertumaxomab - Drug Profile 234
OBI-822/821 - Drug Profile 236
PTC-299 - Drug Profile 238
dovitinib lactate - Drug Profile 240
ADC-1004 - Drug Profile 242
veliparib - Drug Profile 243
lurbinectedin - Drug Profile 245
Autologous CD34+ Derived Dendritic Cells Transduced With an Adenovirus Vector Expressing Inactivated HER-2/Neu - Drug Profile 247
vinflunine ditartrate - Drug Profile 248
Allogeneic Large Multivalent Immunogen Breast Cancer Vaccine + [aldesleukin] - Drug Profile 250
ketoconazole + [docetaxel] - Drug Profile 251
KLF-17 - Drug Profile 252
buparlisib - Drug Profile 253
NK-012 - Drug Profile 256
NLG-8189 - Drug Profile 258
lapatinib ditosylate + trastuzumab - Drug Profile 260
lapatinib ditosylate + trastuzumab - Drug Profile 261
AZD-2014 - Drug Profile 262
AUY-922 - Drug Profile 263
upamostat - Drug Profile 265
Adenoviral Vector Encoding Rat Her-2/neu Vaccine - Drug Profile 266
margetuximab - Drug Profile 267
NRC-AN-019 - Drug Profile 269
Mammaglobin-A DNA Vaccine - Drug Profile 271
bevacizumab - Drug Profile 272
ixabepilone - Drug Profile 276
HER-2/Neu Specific T Cells - Drug Profile 278
AZD-5363 - Drug Profile 279
eniluracil - Drug Profile 280
Peptides Vaccine - Drug Profile 281
trastuzumab biosimilar - Drug Profile 282
trastuzumab biosimilar - Drug Profile 283
LFA-102 - Drug Profile 284
WX-UK1 - Drug Profile 285
TALL-104 - Drug Profile 287
Famitinib - Drug Profile 289
Ad-IL-12 - Drug Profile 290
Foxy-5 - Drug Profile 292
SERD Program - Drug Profile 293
CV-301 - Drug Profile 294
TBL-0905 - Drug Profile 295
LJM-716 - Drug Profile 296
Drug Trageting Vascular Cell Adhesion Molecule-1/Very Late Antigen-4 - Drug Profile 297
decitabine + romidepsin - Drug Profile 298
Eir-070 - Drug Profile 299
Anti microRNA-10b - Drug Profile 300
PN1-Ab - Drug Profile 301
trastuzumab biosimilar - Drug Profile 302
Ire1-Alpha Inhibitors - Drug Profile 303
SGN-LIV1A - Drug Profile 304
Largazole Analogs - Drug Profile 305
doxorubicin dendrimer-based - Drug Profile 306
trastuzumab Biosimilar - Drug Profile 307
trastuzumab Biosimilar - Drug Profile 308
Metastatic Breast Cancer Therapeutics – Drug Profile Updates 309
Metastatic Breast Cancer Therapeutics – Discontinued Products 414
Metastatic Breast Cancer Therapeutics - Dormant Products 417
Metastatic Breast Cancer – Product Development Milestones 423
Featured News & Press Releases 423
Appendix 430
Methodology 430
Coverage 430
Secondary Research 430
Primary Research 430
Expert Panel Validation 430
Contact Us 431
Disclaimer 431

List Of Tables

Number of Products Under Development for Metastatic Breast Cancer, H1 2013 19
Products under Development for Metastatic Breast Cancer – Comparative Analysis, H1 2013 20
Number of Products under Development by Companies, H1 2013 22
Number of Products under Development by Companies, H1 2013 (Contd..1) 23
Number of Products under Development by Companies, H1 2013 (Contd..2) 24
Number of Products under Development by Companies, H1 2013 (Contd..3) 25
Number of Products under Development by Companies, H1 2013 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H1 2013 28
Comparative Analysis by Late Stage Development, H1 2013 29
Comparative Analysis by Mid Clinical Stage Development, H1 2013 30
Comparative Analysis by Early Clinical Stage Development, H1 2013 31
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 32
Products under Development by Companies, H1 2013 33
Products under Development by Companies, H1 2013 (Contd..1) 34
Products under Development by Companies, H1 2013 (Contd..2) 35
Products under Development by Companies, H1 2013 (Contd..3) 36
Products under Development by Companies, H1 2013 (Contd..4) 37
Products under Development by Companies, H1 2013 (Contd..5) 38
Products under Development by Companies, H1 2013 (Contd..6) 39
Products under Investigation by Universities/Institutes, H1 2013 40
Bristol-Myers Squibb Company, H1 2013 41
Johnson & Johnson, H1 2013 42
F. Hoffmann-La Roche Ltd., H1 2013 43
Kyowa Hakko Kirin Co., Ltd., H1 2013 44
Biogen Idec Inc., H1 2013 45
Amgen Inc., H1 2013 46
Adherex Technologies Inc., H1 2013 47
AstraZeneca PLC, H1 2013 48
Eli Lilly and Company, H1 2013 49
GlaxoSmithKline plc, H1 2013 50
Seattle Genetics, Inc., H1 2013 51
Genentech, Inc., H1 2013 52
Nektar Therapeutics, H1 2013 53
Bavarian Nordic A/S, H1 2013 54
MedImmune LLC, H1 2013 55
Celltrion, Inc., H1 2013 57
ZIOPHARM Oncology, Inc., H1 2013 58
Novartis AG, H1 2013 60
Aphios Corporation, H1 2013 61
Biocon Limited, H1 2013 62
Eisai Co., Ltd., H1 2013 63
GTx, Inc., H1 2013 64
Laboratoires Pierre Fabre SA, H1 2013 65
Nippon Kayaku Co., Ltd., H1 2013 66
Pfizer Inc., H1 2013 67
Taiho Pharmaceutical Co., Ltd., H1 2013 68
Cell Therapeutics, Inc., H1 2013 69
Enzon Pharmaceuticals, Inc., H1 2013 70
Celgene Corporation, H1 2013 71
Bayer AG, H1 2013 72
Celldex Therapeutics, Inc., H1 2013 73
Oncolytics Biotech Inc., H1 2013 74
Peregrine Pharmaceuticals, Inc., H1 2013 75
Bionovo, Inc., H1 2013 76
Array BioPharma Inc., H1 2013 77
Starpharma Holdings Limited, H1 2013 78
Jiangsu Hengrui Medicine Co., Ltd., H1 2013 79
Synta Pharmaceuticals Corp., H1 2013 80
Natco Pharma Limited, H1 2013 81
Transgene Biotek Ltd, H1 2013 82
Wilex AG, H1 2013 83
INSYS Therapeutics, Inc., H1 2013 84
Supratek Pharma Inc., H1 2013 85
Meabco A/S, H1 2013 86
BioNumerik Pharmaceuticals, Inc., H1 2013 87
Alligator Bioscience AB, H1 2013 88
MacroGenics, Inc., H1 2013 89
Fresenius Biotech GmbH, H1 2013 90
PTC Therapeutics, Inc., H1 2013 91
Advenchen Laboratories, LLC, H1 2013 92
Syndax Pharmaceuticals, Inc., H1 2013 94
NewLink Genetics Corporation, H1 2013 95
PharmaMar, S.A., H1 2013 96
WntResearch AB, H1 2013 97
Regulus Therapeutics Inc., H1 2013 99
Merus B.V., H1 2013 100
Aragon Pharmaceuticals, Inc., H1 2013 101
EirGen Pharma Ltd., H1 2013 102
Assessment by Monotherapy Products, H1 2013 104
Assessment by Combination Products, H1 2013 105
Assessment by Stage and Route of Administration, H1 2013 107
Assessment by Stage and Molecule Type, H1 2013 110
Metastatic Breast Cancer Therapeutics – Drug Profile Updates 316
Metastatic Breast Cancer Therapeutics – Discontinued Products 421
Metastatic Breast Cancer Therapeutics – Discontinued Products (Contd..1) 422
Metastatic Breast Cancer Therapeutics – Discontinued Products (Contd..2) 423
Metastatic Breast Cancer Therapeutics – Dormant Products 424
Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..1) 425
Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..2) 426
Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..3) 427
Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..4) 428
Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..5) 429

List Of Figures

Number of Products under Development for Metastatic Breast Cancer, H1 2013 19
Products under Development for Metastatic Breast Cancer – Comparative Analysis, H1 2013 20
Products under Development by Companies, H1 2013 21
Products under Investigation by Universities/Institutes, H1 2013 27
Late Stage Products, H1 2013 29
Mid Clinical Stage Products, H1 2013 30
Early Clinical Stage Products, H1 2013 31
Discovery and Pre-Clinical Stage Products, H1 2013 32
Assessment by Monotherapy Products, H1 2013 104
Assessment by Combination Products, H1 2013 105
Assessment by Route of Administration, H1 2013 106
Assessment by Stage and Route of Administration, H1 2013 107
Assessment by Molecule Type, H1 2013 108
Assessment by Stage and Molecule Type, H1 2013 109

Published By: Global Markets Direct
Product Code: Global Markets Direct6253


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100